Two PD-1 checkpoint inhibitors reduced the risk for disease progression or death for people with advanced or recurrent endometrial cancer, according to research presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Both drugs—monoclonal antibodies that restore T-cell activity against tumors—”hit a home run,” according to Rebecca Arend, MD, of the University of Alabama at Birmingham.

In two separate Phase III trials, Jemperli (dostarlimab) plus chemotherapy improved progression-free survival by 72%, while Keytruda (pembrolizumab) plus chemotherapy led to a 70% reduction in the risk for disease progression or death among women whose endometrial tumors had mismatch repair deficiency or high microsatellite instability, meaning they lack mechanisms to repair damaged DNA. However, Keytruda appeared to work better for patients whose tumors lacked these characteristics.